Piers J. Ingram

876 citations

21 papers · 438 indexed · h-index 8

Co-authors: Michael P. H. Stumpf Jaroslav Stark Dipti Thakkar Jerome D. Boyd‐Kirkup Ken Haynes Ruian Ke Thomas Thorne Konrad Paszkiewicz
Topics: Monoclonal and Polyclonal Antibodies Research (10 papers)Cancer Immunotherapy and Biomarkers (8 papers)Gene Regulatory Network Analysis (4 papers)
Cited by: Molecular Biology Immunology Aging
Journals: Journal of Clinical Oncology Blood The Journal of Immunology
Partner nations: United Kingdom United States Singapore

In The Last Decade

Piers J. Ingram

21 papers receiving 426 citations

Peers

Countries citing papers authored by Piers J. Ingram

Since Specialization

Citations

This map shows the geographic impact of Piers J. Ingram's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Piers J. Ingram with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Piers J. Ingram more than expected).

Fields of papers citing papers by Piers J. Ingram

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Piers J. Ingram. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Piers J. Ingram. The network helps show where Piers J. Ingram may publish in the future.

Co-authorship network of co-authors of Piers J. Ingram

This figure shows the co-authorship network connecting the top 25 collaborators of Piers J. Ingram. A scholar is included among the top collaborators of Piers J. Ingram based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Piers J. Ingram. Piers J. Ingram is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Abstract 2660: HMBD-501 - a novel Fc engineered, exatecan-based next generation HER3 targeting antibody drug conjugate shows robust efficacy and tolerability in pre-clinical solid tumor models 2023 ·Cancer Research ·Suhail Ahmed Kabeer Rasheed,Dipti Thakkar,(unknown),(unknown),Akshaya Bansal,(unknown),(unknown),Brendon J. Hanson,Piers J. Ingram,Jerome D. Boyd‐Kirkup	2
2	687P A CRUK phase I/IIA, first in human dose-escalation and expansion trial of HMBD-001 (an anti-HER3 antibody) in patients with advanced HER3 positive solid tumours 2023 ·Annals of Oncology ·Johann S. de Bono,Simon Lord,Christina Yap,Susana Miranda,Gareth J. Veal,(unknown),Alec Paschalis,Clara Péron,Jan Rekowski,Bora Gürel,(unknown),(unknown),Piers J. Ingram,(unknown),Gavin Halbert,Nigel Westwood,(unknown),(unknown),(unknown),(unknown)	1
3	Selective targeting of pathogenic auto-reactive VH4–34 B cells with a rationally developed anti-VH4–34 antibody offers a new therapeutic approach for autoimmune disorders 2023 ·The Journal of Immunology ·(unknown),Dipti Thakkar,(unknown),Warren Lee,(unknown),(unknown),Brendon J. Hanson,Konrad Paszkiewicz,Piers J. Ingram,Jerome D. Boyd‐Kirkup	2
4	A phase 1 first-in-human clinical trial of HMBD-002, an IgG4 monoclonal antibody targeting VISTA, in advanced solid tumors. 2023 ·Journal of Clinical Oncology ·Jordi Rodón,Joshua J. Gruber,Melinda L. Telli,Monica Mita,Alain C. Mita,Joseph W. Kim,Miguel A. Villalona‐Calero,Meera Patel,Shalini S. Yadav,Padmanee Sharma,Tom Haber,(unknown),(unknown),Bhushan Dharmadhikari,Dipti Thakkar,(unknown),Leah DiMascio,Eric K. Rowinsky,Piers J. Ingram,Jerome D. Boyd‐Kirkup	6
5	Rationally targeted anti-VISTA antibody that blockades the C-C’ loop region can reverse VISTA immune suppression and remodel the immune microenvironment to potently inhibit tumor growth in an Fc independent manner 2022 ·Journal for ImmunoTherapy of Cancer ·Dipti Thakkar,(unknown),Bhushan Dharmadhikari,Siyu Guan,(unknown),Shreya Kar,Nikhil Kumar Tulsian,Joshua J. Gruber,Leah DiMascio,Konrad Paszkiewicz,Piers J. Ingram,Jerome D. Boyd‐Kirkup	46
6	532 Anti-VISTA antibody HMBD-002 reprograms tumour associated macrophages and promotes cytotoxic T cell response 2022 ·Regular and Young Investigator Award Abstracts ·Bhushan Dharmadhikari,Dipti Thakkar,Olga Zharkova,(unknown),(unknown),Konrad Paszkiewicz,Piers J. Ingram,Jerome D. Boyd‐Kirkup	2
7	Abstract P197: An anti-HER3 antibody, HMBD-001, that uniquely binds to and blocks the HER3 heterodimerization interface, shows superior tumor growth inhibition in biomarker-defined preclinical cancer models including NRG1-fusion driven cancers 2021 ·Molecular Cancer Therapeutics ·Dipti Thakkar,(unknown),Shreya Kar,Namita Gandhi,Konrad Paszkiewicz,Piers J. Ingram,Jerome D. Boyd‐Kirkup	5
8	HMBD-002 is a novel, neutralizing, anti-VISTA antibody exhibiting strong preclinical efficacy and safety, being developed as a monotherapy and in combination with pembrolizumab. 2021 ·Journal of Clinical Oncology ·Leah DiMascio,Dipti Thakkar,Namita Gandhi,Siyu Guan,Eric K. Rowinsky,Piers J. Ingram,Jerome D. Boyd‐Kirkup	7
9	469 A phase 1 first in human study of HMBD-002, an IgG4 monoclonal antibody targeting VISTA, as a monotherapy and combined with pembrolizumab in patients with advanced solid malignancies 2021 ·Regular and Young Investigator Award Abstracts ·Leah DiMascio,Dipti Thakkar,Siyu Guan,Eric K. Rowinsky,Jordi Rodón,Joshua J. Gruber,Benjamin Musher,Joseph Kim,Alain C. Mita,Monica Mita,Piers J. Ingram,Jerome D. Boyd‐Kirkup	3
10	10D1F, an Anti-HER3 Antibody That Uniquely Blocks the Receptor Heterodimerization Interface, Potently Inhibits Tumor Growth Across a Broad Panel of Tumor Models 2020 ·Molecular Cancer Therapeutics ·Dipti Thakkar,Vicente Sancenón,(unknown),Siyu Guan,Zhihao Wu,(unknown),Konrad Paszkiewicz,Piers J. Ingram,Jerome D. Boyd‐Kirkup	13
11	Abstract 1729: Integrative immune profiling of syngeneic tumor models provides predictive immune signatures for treatment response with HMBD002, a novel anti-VISTA neutralizing antibody 2018 ·Cancer Research ·Jerome D. Boyd‐Kirkup,Dipti Thakkar,Konrad Paszkiewicz,Piers J. Ingram	6
12	HMBD004, a Novel Anti-CD47xCD33 Bispecific Antibody Displays Potent Anti-Tumor Effects in Pre-Clinical Models of AML 2017 ·Blood ·Jerome D. Boyd‐Kirkup,Dipti Thakkar,Peter Bräuer,Jianbiao Zhou,Wee Joo Chng,Piers J. Ingram	18
13	Abstract 587: HMBD002, a novel neutralizing antibody targeting a specific epitope on the co-inhibitory immune checkpoint receptor VISTA, displays potent anti-tumor effects in pre-clinical models 2017 ·Cancer Research ·Piers J. Ingram,Dipti Thakkar,Jerome D. Boyd‐Kirkup	7
14	An Integrative Model of Ion Regulation in Yeast 2013 ·PLoS Computational Biology ·Ruian Ke,Piers J. Ingram,Ken Haynes	37
15	A systems biology analysis of long and short-term memories of osmotic stress adaptation in fungi 2012 ·BMC Research Notes ·Tao You,Piers J. Ingram,Mette D. Jacobsen,Emily Cook,(unknown),Thomas Thorne,Megan D. Lenardon,(unknown),M. Carmen Romano,Marco Thiel,Michael P. H. Stumpf,Neil A. R. Gow,Ken Haynes,Celso Grebogi,Jaroslav Stark,Alistair J. P. Brown	32
16	An anatomical study of the myelination of human laryngeal nerves 2011 ·The Journal of Laryngology & Otology ·Jason C. Fleming,(unknown),Piers J. Ingram,Meredydd Harries	2
17	The Degree Distribution of Networks: Statistical Model Selection 2011 ·Methods in molecular biology ·William Kelly,Piers J. Ingram,Michael P. H. Stumpf	7
18	Nonidentifiability of the Source of Intrinsic Noise in Gene Expression from Single-Burst Data 2008 ·PLoS Computational Biology ·Piers J. Ingram,Michael P. H. Stumpf,Jaroslav Stark	26
19	The effects of incomplete protein interaction data on structural and evolutionary inferences 2006 ·BMC Biology ·Eric de Silva,Thomas Thorne,Piers J. Ingram,(unknown),Jonathan Swire,Carsten Wiuf,Michael P. H. Stumpf	52
20	Network motifs: structure does not determine function 2006 ·BMC Genomics ·Piers J. Ingram,Michael P. H. Stumpf,Jaroslav Stark	162

About Piers J. Ingram

Piers J. Ingram is a scholar working on Oncology, Radiology, Nuclear Medicine and Imaging and Immunology, having authored 21 papers that have together received 438 indexed citations. Recurring topics across this work include Monoclonal and Polyclonal Antibodies Research (10 papers), Cancer Immunotherapy and Biomarkers (8 papers) and Gene Regulatory Network Analysis (4 papers). The work is most often cited by research in Molecular Biology (289 citations), Immunology (76 citations) and Aging (6 citations). Piers J. Ingram has collaborated with scholars based in United Kingdom, United States and Singapore. Frequent co-authors include Michael P. H. Stumpf, Jaroslav Stark, Dipti Thakkar, Jerome D. Boyd‐Kirkup, Ken Haynes, Ruian Ke, Thomas Thorne, Konrad Paszkiewicz, Jonathan Swire and Siyu Guan. Their work appears in journals such as Journal of Clinical Oncology, Blood and The Journal of Immunology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact